CPT code 0087U identifies a Proprietary Laboratory Analyses (PLA) test — the Molecular Microscope® MMDx—Heart assay from Kashi Clinical Laboratories — that measures mRNA levels in heart transplant biopsy tissue and compares results to a reference library to identify causes of graft dysfunction. This PLA code matters nationally because it denotes a single-manufacturer, high-complexity molecular diagnostic service used in transplant management and can affect coverage, coding consistency, and lab reimbursement decisions across insurers.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of the clinical purpose and lab setting for the assay, a summary of which payers are included in the review, and an outline of the topics typically addressed in payer and policy assessments for PLA tests. These topics include payer coverage patterns, billing and coding practice considerations for proprietary molecular tests, and clinical context for transplant surveillance and diagnostic differentiation.

The publication presents benchmarks and policy-relevant items for national audiences, highlights payer-specific coverage themes where available, and provides clinical context to inform coding and billing workflows related to proprietary transplant diagnostic assays. Data not available in the input will be noted where applicable.